A Medical Device Daily
Intermagnetics General (Latham, New York) reported filing a shelf registration with the Securities and Exchange Commission (SEC) enabling it to offer preferred stock, common stock, senior and subordinated debt and warrants, as well as units and purchase contracts that may include one or more of those securities. It did not specify the number of shares or proposed pricing.
“It is both timely and appropriate to add a shelf registration statement to our portfolio of tools to pursue our strategic objectives,“ said Glenn Epstein, CEO and chairman. “While we have no imminent needs or present plans to issue securities, we are positioning ourselves to be increasingly nimble and flexible . . .“
Intermagnetics offers products in the MRI market, plus what it terms “expanding businesses within medical devices that encompass in vivo diagnostic imaging . . . and in vivo patient care.“ The company also participates in superconducting applications for energy technology.
Aesthera (Pleasanton, California), a developer of photopneumatic-based aesthetic treatment systems, reported securing $11 million in a third round of venture funding, led by Kleiner Perkins Caufield & Byers (KPCB), with participation from existing investors MedVenture Associates and Adams Street Partners.
Aesthera says it offers the only clinically proven no-pain treatment for permanent hair reduction and skin rejuvenation. It said that the additional funds would be used to continue driving R&D for new applications of its Photo-pneumatic Technology (PPx), and to expand its global sales channels and marketing efforts.
PPx combines pneumatic energy with a broadband light source that positions the target tissue, painlessly treats the skin and hair, and cleans the skin's pores.
Alon Maor, president and CEO, said “Our rapidly growing installed base is the result of physicians' success with our clinically proven technology for safe, effective, pain-free light-based aesthetic treatments.“
Dana Mead Jr., partner at KPCB and former president of Guidant Vascular Intervention, has been appointed to serve on the Aesthera board.
Aesthera said it would introduce the PPx system at the annual meeting of the American Academy of Dermatology (Schaumburg, Illinois) next month in San Francisco.